Kyverna Therapeutics

Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’
BioPharma Dive
Mon, 09/16/24 - 10:14 pm
Kyverna Therapeutics
Gilead Sciences
Kite Pharma
CAR-T
cell therapy
Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder
Pharma Voice
Fri, 07/19/24 - 11:39 am
Kyverna Therapeutics
CAR-T
stiff person syndrome
autoimmune disease
Ones to watch - five upcoming companies on the CAR-T scene
Biopharma Reporter
Mon, 07/8/24 - 11:46 am
CAR-T
Cargo Therapeutics
Capstan Therapeutics
Kyverna Therapeutics
Ucello Bio
Verismo Therapeutics
Biopharma IPOs From the First Half of 2024
BioSpace
Thu, 05/30/24 - 11:17 am
IPOs
biotewch
CG Oncology
Kyverna Therapeutics
ArriVent Biopharma
Alto Neuroscience
Contineum Therapeutics
Boundless Bio
Fractyl Health
Metagenomi
Telomir
Rapport Therapeutics
Telix Pharmaceuticals
Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24
Fierce Biotech
Wed, 04/3/24 - 11:36 am
biotech
M&A
IPOs
CG Oncology
Kyverna Therapeutics
Contineum Therapeutics
Boundless Bio
CymaBay Therapeutics
Gilead Sciences
MorphoSys
Novartis
Fusion Pharmaceuticals
AstraZeneca
Ambryx
JNJ
Inhibrix
Aventis
Kyverna reports first use of KYV-101 for multiple sclerosis treatment
Clinical Trials Arena
Tue, 04/2/24 - 11:27 am
Kyverna Therapeutics
KYV-101
multiple sclerosis
Everyone's Talking About These 2 Biotech IPO Stocks
Motley Fool
Sun, 02/25/24 - 08:55 pm
biotech
IPOs
Kyverna Therapeutics
CG Oncology
Kyverna CEO Peter Maag on courting investors in a ‘volatile’ IPO market
BioPharma Dive
Mon, 02/12/24 - 11:47 am
Kyverna Therapeutics
IPOs
Peter Maag
Kyverna IPO adds to biotech momentum with $319M fundraise
BioPharma Dive
Thu, 02/8/24 - 11:07 am
Kyverna Therapeutics
IPOs
autoimmune diseases
Kyverna sets IPO range, eyeing $180M haul to fund broad autoimmune CAR-T clinical trial program
Fierce Biotech
Thu, 02/1/24 - 11:19 am
Kyverna Therapeutics
IPOs
cell therapy
autoimmune disease
2024 Brings Surprising Early Surge of Biotech IPOs
BioSpace
Fri, 01/19/24 - 09:43 am
biotech
IPOs
CG Oncology
Alto Neuroscience
ArriVent Biopharma
Kyverna Therapeutics
Metagenomi
FDA clears Kyverna’s IND for scleroderma therapy
Pharmaceutical Business Review
Thu, 10/12/23 - 10:06 am
Kyverna Therapeutics
KYV-101
scleroderma
FDA
Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy
BioPharma Dive
Thu, 08/3/23 - 10:12 am
Kyverna Therapeutics
lupus
Gilead Sciences
Treg cell therapy
Kyverna Files First IND to Leverage CAR-T Therapy for Lupus
BioSpace
Thu, 10/20/22 - 10:32 am
Kyverna Therapeutics
KYV-101
CAR-T
lupus nephritis
‘Treg’ cell therapy: bringing CAR-T to autoimmune disease
BioPharma Dive
Tue, 08/16/22 - 10:52 am
Treg cell therapy
autoimmune disease
Kyverna Therapeutics
Quell Therapeutics
Sonoma Biotherapeutics
GentiBio
Abata Therapeutics
Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising
Fierce Biotech
Wed, 01/26/22 - 10:38 am
Gilead Sciences
Kyverna Therapeutics
funding
cell therapy